tbuckley/cabot-search huggingface dataset:
The Harmonising Outcome Measures for Eczema (HOME) implementation roadmap
Authors: Yael A Leshem, Eric L Simpson, Christian Apfelbacher, Phyllis I Spuls, Kim S Thomas, Jochen Schmitt, Laura Howells, Louise A A Gerbens, Michael E Jacobson, Norito Katoh, Hywel C Williams
Journal: British Journal of Dermatology (2023)

Abstract Background Core outcome sets (COS) are consensus-driven sets of minimum outcomes that should be measured and reported in all clinical trials. COS aim to reduce heterogeneity in outcome measurement and reporting, and selective outcome reporting. Implementing COS into clinical trials is challenging. Guidance to improve COS uptake in dermatology is lacking. Objectives To develop a structured practical guide to COS implementation. Methods Members of the Harmonising Outcome Measurement for Eczema (HOME) executive committee developed an expert opinion-based roadmap founded on a combination of a review of the COS implementation literature, the Core Outcome Measures in Effectiveness Trials (COMET) initiative resources, input from HOME members and experience in COS development and clinical trials. Results The data review and input from HOME members was synthesized into themes, which guided roadmap development: (a) barriers and facilitators to COS uptake based on stakeholder awareness/engagement and COS features; and (b) key implementation science principles (assessment-driven, data-centred, priority-based and context-sensitive). The HOME implementation roadmap follows three stages. Firstly, the COS uptake scope and goals need to be defined. Secondly, during COS development, preparation for future implementation is supported by establishing the COS as a credible evidence-informed consensus by applying robust COS development methodology, engaging multiple stakeholders, fostering sustained and global engagement, emphasizing COS ease of use and universal applicability, and providing recommendations on COS use. Thirdly, incorporating completed COS into primary (trials) and secondary (reviews) research is an iterative process starting with mapping COS uptake and stakeholders’ attitudes, followed by designing and carrying out targeted implementation projects. Main themes for implementation projects identified at HOME are stakeholder awareness/engagement; universal applicability for different populations; and improving ease-of-use by reducing administrative and study burden. Formal implementation frameworks can be used to identify implementation barriers/facilitators and to design implementation strategies. The effect of these strategies on uptake should be evaluated and implementation plans adjusted accordingly. Conclusions COS can improve the quality and applicability of research and, so, clinical practice but can only succeed if used and reported consistently. The HOME implementation roadmap is an extension of the original HOME roadmap for COS development and provides a pragmatic framework to develop COS implementation strategies.
A shared novelty-seeking basis for creativity and curiosity
Authors: Tal Ivancovsky, Shira Baror, Moshe Bar
Journal: Behavioral and Brain Sciences (2023)

Abstract Curiosity and creativity are central pillars of human growth and invention. Although they have been studied extensively in isolation, the relationship between them has not yet been established. We propose that both curiosity and creativity emanate from the same mechanism of novelty seeking. We first present a synthesis showing that curiosity and creativity are affected similarly by a number of key cognitive faculties such as memory, cognitive control, attention, and reward. We then review empirical evidence from neuroscience research, indicating that the same brain regions are involved in both curiosity and creativity, focusing on the interplay between three major brain networks: the default mode network, the salience network, and the executive control network. After substantiating the link between curiosity and creativity, we propose a novelty-seeking model (NSM) that underlies them and suggests that the manifestation of the NSM is governed by one's state of mind.
Trends in Delirium and New Antipsychotic and Benzodiazepine Use Among Hospitalized Older Adults Before and After the Onset of the COVID-19 Pandemic
Authors: Christina Reppas-Rindlisbacher, Alexa Boblitz, Robert A. Fowler, Lauren Lapointe-Shaw, Kathleen A. Sheehan, Therese A. Stukel, Paula A. Rochon
Journal: JAMA Network Open (2023)

The COVID-19 pandemic caused large disruptions to health care for hospitalized older adults. The incidence and management of delirium may have been affected by high rates of COVID-19 infection, staffing shortages, overwhelmed hospital capacity, and changes to visitor policies.
Maternal vitamin D–related metabolome and offspring risk of asthma outcomes
Authors: Min Kim, Nicklas Brustad, Mina Ali, Gözde Gürdeniz, Morten Arendt, Augusto A. Litonjua, Craig E. Wheelock, Rachel S. Kelly, Yulu Chen, Nicole Prince, Feng Guo, Xiaobo Zhou, Jakob Stokholm, Klaus Bønnelykke, Scott T. Weiss, Hans Bisgaard, Jessica Lasky-Su, Bo Chawes
Journal: Journal of Allergy and Clinical Immunology (2023)

Gestational vitamin D deficiency is implicated in development of respiratory diseases in offspring, but the mechanism underlying this relationship is unknown.
The impact of sleep disturbance on pain perception: A systematic review examining the moderating effect of sex and age
Authors: Shima Rouhi, Jamie Topcu, Natalia Egorova-Brumley, Amy S. Jordan
Journal: Sleep Medicine Reviews (2023)

Females have increased pain sensitivity and are more vulnerable to chronic pain conditions. Sleep disturbances are comorbid with chronic pain and exacerbate pain symptoms. Different types of sleep disturbance affect pain perception distinctly, but it is not clear if these effects are equal in men and women. This systematic review investigated potential differences in how sleep disturbance affects pain in males and females. We searched EBSCO, MEDLINE, Psych INFO, Science Direct, and Web of Science from January 2001 to November 2022 and found 38 studies with 978 participants. Separate random-effects models were used to estimate the pooled effect sizes based on standardized mean differences (SMDs) of experimental sleep disturbance paradigms on various pain outcomes. Sex moderated the effect of sleep disturbance on pain facilitation (SMD = 0.13; 95%CI: 0.004 to 0.022; p=.009) and pain inhibition (SMD = 0.033; 95%CI: 0.011 to 0.054; p=.005), with increased facilitation and decreased inhibition in females, but the opposite effect in males. Further, age moderated the effects of total sleep deprivation (SMD = -0.194; 95%CI -0.328 to -0.060; p=.008) on pain sensitivity and fragmented sleep (SMD = -0.110; 95%CI: 0.148 to -0.072; p<.001) on pain threshold. While the moderating effect of sex and age on the sleep-pain relationship was small, these factors need to be considered in future sleep-pain research.
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
Authors: H. von der Maase, S.W. Hansen, J.T. Roberts, L. Dogliotti, T. Oliver, M.J. Moore, I. Bodrogi, P. Albers, A. Knuth, C.M. Lippert, P. Kerbrat, P. Sanchez Rovira, P. Wersall, S.P. Cleall, D.F. Roychowdhury, I. Tomlin, C.M. Visseren-Grul, P.F. Conte
Journal: Journal of Clinical Oncology (2023)

Gemcitabine plus cisplatin (GC) and methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) were compared in patients with locally advanced or metastatic transitional-cell carcinoma (TCC) of the urothelium.
New narratives for a healthy planet: creative writing and art projects reveal We Still Have a Chance
Authors: Hugh Gerald Arthur Roberts, Rosa Barciela, Sally Flint, Ian Fussell, Eliana Maestri, Cecilia Mañosa Nyblon, Adam Marple, Fatma Sabet, Peter Stott
Journal: The Lancet Planetary Health (2023)

The climate crisis is also a crisis of language, communication, and translation.1 At the Intergovernmental Panel on Climate Change meeting in Shanghai in January, 2001, for example, Saudi Arabia refused to support a motion saying that it is likely that man-made greenhouse gases have contributed substantially to global warming over the previous 50 years. This refusal was "on the grounds that 'substantial' did not translate into Arabic".2 Although language can be weaponised in ways that ultimately harm planetary health, this Comment tells the story behind a series of projects between scientists at the Met Office (Exeter, UK) and creative researchers as well as health professionals at the University of Exeter, to harness the power of words to tell more hopeful and emotionally engaged stories; we are sharing practice and insights should others wish to adopt and adapt them.
Promising the Earth
Authors: None The Lancet Planetary Health
Journal: The Lancet Planetary Health (2023)

When we think about and discuss progress towards the sustainable development goals (SDGs), for example, how effectively we are cutting carbon emissions, halting biodiversity loss, or eradicating poverty, there is a tension between a desire to recognise progress and the need to acknowledge how far we still have to go. Focussing on progress can help shift dialogue from being problem focussed to solution orientated; this can be energizing and facilitate movement building. By contrast focussing on how much more we still need to do is frequently seen as negative, uninspiring, potentially anxiety inducing and even defeatist, all of this may be true to an extent and yet to measure progress we need to know how far we are from our goals as well as how far we have got from the startling line.
Fatal Drug Overdose Risks of Health Care Workers in the United States
Authors: Mark Olfson, Candace M. Cosgrove, Melanie M. Wall, Carlos Blanco
Journal: Annals of Internal Medicine (2023)

Despite an unprecedented increase in drug overdose deaths in the United States, the risks faced by U.S. health care workers, who often have access to controlled prescription drugs, are not known. To estimate risks for drug overdose death among health care workers relative to non-health care workers. Prospective cohort study. United States. Health care workers (n = 176 000) and non-health care workers (n = 1 662 000) aged 26 years or older surveyed in 2008 and followed for cause of death through 2019. Age- and sex-standardized drug overdose deaths were determined for 6 health care worker groups (physicians, registered nurses, other treating or diagnosing health care workers, health technicians, health care support workers, and social or behavioral health workers) and non-health care workers. Adjusted drug overdose death hazards (and 95% CIs) were also evaluated, with adjustment for age, sex, race/ethnicity, marital status, education, income, urban or rural residence, and region. Approximately 0.07% of our study sample died of a drug overdose during follow-up. Among health care workers, annual standardized rates of drug overdose death per 100 000 persons ranged from 2.3 (95% CI, 0 to 4.8) for physicians to 15.5 (CI, 9.8 to 21.2) for social or behavioral health workers. Compared with those for non-health care workers, the adjusted hazards of total drug overdose death were significantly increased for social or behavioral health workers (adjusted hazard ratio, 2.55 [CI, 1.74 to 3.73]), registered nurses (adjusted hazard ratio, 2.22 [CI, 1.57 to 3.13]), and health care support workers (adjusted hazard ratio, 1.60 [CI, 1.19 to 2.16]), but not for physicians (adjusted hazard ratio, 0.61 [CI, 0.19 to 1.93]), other treating or diagnosing health care workers (adjusted hazard ratio, 0.93 [CI, 0.44 to 1.95]), or health technicians (adjusted hazard ratio, 1.13 [CI, 0.75 to 1.68]). Results were generally similar for opioid-related overdose deaths and unintentional overdose deaths. Unmeasured confounding, uncertain validity of cause of death, and one-time assessment of occupation. Registered nurses, social or behavioral health workers, and health care support workers were at increased risk for drug overdose death, suggesting the need to identify and intervene on those at high risk. National Heart, Lung, and Blood Institute.
Highlights of the NCCN Oncology Research Program
Journal: Journal of the National Comprehensive Cancer Network (2023)

This is a phase Ib/II investigator-initiated, open-label trial of the combination of oral decitabine/cedazuridine (DEC-C) and nivolumab treatments.Mucosal melanomas are characterized by excess methylation-related immunosuppression.DEC-C is used as a hypomethylating agent in an attempt to reactivate the RIG-I/interferon signaling pathway prior to treating
Adolescent and Young Adult (AYA) Oncology, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Authors: Smita Bhatia, Alberto S. Pappo, Melissa Acquazzino, Wendy A. Allen-Rhoades, Marie Barnett, Scott C. Borinstein, Robert Casey, Sun Choo, Rashmi Chugh, Shira Dinner, Ralph Ermoian, Douglas Fair, Noah Federman, Jeanelle Folbrecht, Shipra Gandhi, Julie Germann, Robert Goldsby, Robert Hayashi, Alex Y. Huang, Mary S. Huang, Linda A. Jacobs, Cathy Lee-Miller, Michael P. Link, John A. Livingston, Maryam Lustberg, Marcio Malogolowkin, Kevin C. Oeffinger, Christine A. Pratilas, Damon Reed, Jodi Skiles, Margaret von Mehren, Nicholas Yeager, Sarah Montgomery, Lisa Hang
Journal: Journal of the National Comprehensive Cancer Network (2023)

This selection from the NCCN Guidelines for Adolescent and Young Adult (AYA) Oncology focuses on considerations for the comprehensive care of AYA patients with cancer. Compared with older adults with cancer, AYA patients have unique needs regarding treatment, fertility counseling, psychosocial and behavioral issues, and supportive care services. The complete version of the NCCN Guidelines for Adolescent and Young Adult (AYA) Oncology addresses additional aspects of caring for AYA patients, including risk factors, screening, diagnosis, and survivorship.
Antioxidative and antibacterial gallium (III)-phenolic coating for enhanced osseointegration of titanium implants via pro-osteogenesis and inhibiting osteoclastogenesis
Authors: Kui Xu, Caiyun Mu, Chi Zhang, Sijie Deng, Shan Lin, Linlin Zheng, Weizhen Chen, Qiqing Zhang
Journal: Biomaterials (2023)
Changes in Prescribing Patterns in Stage III Colon Cancer
Authors: Fang-Shu Ou, Daniel J. Walden, Joseph J. Larson, Sandra Kang, Cassia R. Griswold, Benjamin E. Ueberroth, Bhamini Patel, Amber Draper, Puneet Raman, Olatunji B. Alese, Mohamad B. Sonbol, Tanios S. Bekaii-Saab, Christina S. Wu, Daniel H. Ahn
Journal: Journal of the National Comprehensive Cancer Network (2023)

Background: For patients with resected stage III colon cancer, 6 months of adjuvant fluoropyrimidine-based chemotherapy has been the standard of care. The IDEA collaboration aimed to evaluate whether 3 months of adjuvant chemotherapy was noninferior to 6 months. Despite failing to meet its primary endpoint, the subgroup analyses demonstrated noninferiority based on regimen and treatment duration when a risk-stratified approach was used. Patients and Methods: To evaluate the impact of the results of the IDEA collaboration, we evaluated adjuvant chemotherapy prescribing practice patterns, including planned adjuvant treatment regimen and duration from January 1, 2016, to January 31, 2021. The time period was selected to evaluate chemotherapy prescribing patterns prior to the abstract presentation of the IDEA collaboration in June 2017 and after full manuscript publication in March 2018. Results: A total of 399 patients with stage III colon cancer who received adjuvant chemotherapy were included in the analysis. A significant increasing trend for use of 3 months of adjuvant chemotherapy was observed after presentation of the IDEA abstract ( P &lt;.001). A significant change in CAPOX (capecitabine/oxaliplatin) prescribing was also observed, increasing from 14% of patients prior to presentation of the IDEA abstract to 48% after presentation ( P &lt;.001). Comparing 3 months of CAPOX with 6 months of FOLFOX (fluorouracil/leucovorin/oxaliplatin), 3 months of CAPOX use also steadily increased over time (adjusted odds ratio [aOR], 1.28; 95% CI, 1.20–1.37; P &lt;.001). Among subgroups of interest, no differences in adoption of CAPOX were observed. The adoption of 3 months of CAPOX was similar in patients with low-risk cancer (aOR, 1.27; 95% CI, 1.17–1.37) and those with high-risk cancer (aOR, 1.31; 95% CI, 1.16–1.47). Conclusions: Despite the IDEA collaboration failing to demonstrate noninferiority of 3 months’ duration of adjuvant therapy compared with 6 months, the findings have influenced practice prescribing patterns, favoring CAPOX and a shorter duration of planned adjuvant treatment.
Compound Kushen Injection Reduces Severe Toxicity and Symptom Burden Associated With Curative Radiotherapy in Patients With Lung Cancer
Authors: Jie Liu, Qingxi Yu, Xin Shelley Wang, Qiuling Shi, Jun Wang, Fan Wang, Simeng Ren, Jiayue Jin, Baojin Han, Wenzheng Zhang, Xueyao Su, Shuanghu Yuan, Hongsheng Lin
Journal: Journal of the National Comprehensive Cancer Network (2023)

Background: Radiotherapy (RT) causes adverse events for which there are no effective treatments. This study investigated the clinical benefits of compound Kushen injection (CKI) in managing radiation injury in patients with lung cancer. Methods: A multicenter, open-label, randomized clinical trial randomly assigned patients with lung cancer to receive either CKI (20 mL/d for at least 4 weeks) integrated with curative RT (RT + CKI group; n=130) or RT alone (control group; n=130). The primary outcome was the incidence of grade ≥2 radiation-induced lung injury (RILI) in the lungs, esophagus, or heart. Secondary outcomes included patient-reported symptoms, quality of life, objective response rate (ORR), and toxic effects. Results: During the 16-week trial, the RT + CKI group had a significantly lower incidence of grade ≥2 RT-related injury than the control group (12.3% [n=16] vs 23.1% [n=30]; P =.02). Compared with the control group, the RT + CKI group experienced a significant decrease in moderate-to-severe symptoms of fatigue, cough, and pain ( P &lt;.001 for the treatment and time interaction term); significantly less physical symptom interference ( P =.01); and significantly better quality of life by the end of the trial ( P &lt;.05). No statistically significant difference in ORR was found. Adverse reactions associated with CKI were rare. Conclusions: This study demonstrated low toxicity of CKI and its effectiveness in patients with lung cancer in reducing the incidence of grade ≥2 RILI and symptom burden, improving patients' quality of life.
Targeting Trop-2 as a Cancer Driver
Authors: Emanuela Guerra, Marco Trerotola, Saverio Alberti
Journal: Journal of Clinical Oncology (2023)

Article Tools UNDERSTANDING THE PATHWAY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2–Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non–Small-Cell Lung Cancer: TROPION-PanTumor01. June 16, 2023 ARTICLE CITATION DOI: 10.1200/JCO.23.01207 Journal of Clinical Oncology - published online before print August 7, 2023 PMID: 37549340 Targeting Trop-2 as a Cancer Driver Emanuela Guerra , PhD1,2xEmanuela GuerraSearch for articles by this author; Marco Trerotola , PhD1,2xMarco TrerotolaSearch for articles by this author; and Saverio Alberti , MD, PhD3xSaverio AlbertiSearch for articles by this author Show More 1Laboratory of Cancer Pathology, Center for Advanced Studies and Technology (CAST), G. d'Annunzio University of Chieti-Pescara, Chieti, Italy2Department of Medical, Oral and Biotechnological Sciences, G. d'Annunzio University of Chieti-Pescara, Chieti, Italy3Unit of Medical Genetics, Department of Biomedical Sciences—BIOMORF, University of Messina, Messina, Italy https://doi.org/10.1200/JCO.23.01207 First Page Full Text PDF Figures and Tables © 2023 by American Society of Clinical OncologyAUTHOR CONTRIBUTIONSConception and design: All authorsCollection and assembly of data: All authorsData analysis and interpretation: Emanuela Guerra, Saverio AlbertiManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTTargeting Trop-2 as a Cancer DriverThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Emanuela GuerraStock and Other Ownership Interests: Mediterranea Theranostic SrlResearch Funding: Mediterranea Theranostic SrlPatents, Royalties, Other Intellectual Property: Inventor in patents WO2016087651 and WO2017084763,Saverio AlbertiLeadership: Oncoxx BiotechStock and Other Ownership Interests: Oncoxx BiotechResearch Funding: Oncoxx BiotechPatents, Royalties, Other Intellectual Property: novel anti-cancer drugs and companion diagnosticsTravel, Accommodations, Expenses: Oncoxx BiotechNo other potential conflicts of interest were reported. Companion First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2–Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non–Small-Cell Lung Cancer: TROPION-PanTumor01
Hematologic Malignancy: Who Cares in the End? A Retrospective Cohort Study of Markers of Quality End-of-Life Care
Authors: Briony Shaw, Catriona Parker, Stephen Opat, Jake Shortt, Peter Poon
Journal: Journal of the National Comprehensive Cancer Network (2023)

Early palliative care is increasingly used in solid organ malignancy but is less established in patients with hematologic malignancy. Disease-related factors increase the demand for hospitalization, treatment, and supportive care in patients with hematologic malignancy. The terminal phase of illness in patients with hematologic malignancy can be difficult to predict, resulting in complexities in establishing a standard for quality end-of-life care.This is a retrospective single-center cohort study of adult patients with hematologic malignancy who died between October 2019 and July 2022. Patients were identified, and disease characteristics, therapy, and outcomes were extracted from medical records. Descriptive statistics are reported and univariate analyses were performed across a range of factors to assess for associations.A total of 229 patients were identified, with a median age of 77 years and 35% female. In the final 30 days of life, 65% presented to the emergency department, 22% had an ICU admission, 22% had an invasive procedure, 48% received cytotoxic therapy, 61% received a RBC transfusion, and 46% received a platelet transfusion. Use of intensive chemotherapy was particularly associated with hospitalization and ICU admission. A total of 74% referred to palliative care, with a median time from referral to death of 13 days. Of these patients, one-third were referred within the last 5 days of life. In terms of place of death, 54% died in the acute hospital setting and 30% in hospice, with a median hospice length of stay of 4 days.These findings highlight the need for further research into quality indicators for end of life in hematologic malignancy and earlier integration of specialist supportive and palliative care in both inpatient and outpatient settings.